Dr Baretti delivered an illuminating presentation at the 2026 Annual Cholangiocarcinoma Foundation Conference on the role of clinical trials in advancing cholangiocarcinoma (CCA) treatment. Her talk aimed to address common misconceptions, provide clarity, and highlight the opportunities clinical trials offer to patients facing this rare and complex cancer.
Advances in molecular profiling have revealed that CCA comprises multiple subtypes driven by distinct genetic alterations, enabling more personalized treatment approaches. Clinical trials play a central role in this shift, offering access to targeted therapies, novel combinations, and strategies designed to extend survival and to improve quality of life.
Importantly, clinical trials are no longer considered a last resort. Instead, they are increasingly integrated earlier in treatment decision-making, giving patients access to emerging therapies when they may have the greatest impact. Modern trial designs are also more adaptive and efficient, often evaluating safety, efficacy, and optimal dosing while tailoring treatments to specific tumor profiles.
Clinical trial participation is often discouraged by misconceptions that they are unsafe, involve placebo instead of real treatment, replace standard care, or are only used when other treatment options have not worked; however, they are built on strong scientific rationale and prioritize patient safety through rigorous oversight and close monitoring. Placebos are rarely used in oncology trials, and patients do not receive less than the standard of care. Eligibility criteria are designed to ensure appropriate patient selection, protecting participants while improving the reliability of results.
Participation in a clinical trial can provide early access to innovative therapies and expand treatment options beyond established care, an important consideration in CCA, where options may be limited. However, involvement may require additional time, travel, and coordination, making it essential for patients to weigh these factors in discussion with their care teams.
Ongoing progress is also supported by accelerated approval pathways, which allow promising therapies, such as FGFR inhibitors, to reach patients more quickly while additional data are collected to confirm long-term benefit
Ultimately, clinical trials remain a driving force behind innovation in CCA care. By engaging early and utilizing trusted resources, patients can play an active role in expanding their treatment options while contributing to advances that may benefit others in the future.
Source: Baretti M. Clinical trials in cholangiocarcinoma: myths, facts, and opportunities. Presented at: 2026 Annual Cholangiocarcinoma Foundation Conference. May 1-3, 2026; Salt Lake City, UT.
To sign up for our newsletter or print publications, please enter your contact information below.
